ApoG2 inhibits the antiapoptotic protein, Mcl‑1, and induces mitochondria‑dependent apoptosis in human colorectal cancer cells

Li,Tianxiao; Yuan,Gang; Zhang,Lin; Ye,Lijun; Li,Shuxia; Fan,Yuhua; Sun,Jian

doi:10.3892/mmr.2015.4299

ApoG2 inhibits the antiapoptotic protein, Mcl‑1, and induces mitochondria‑dependent apoptosis in human colorectal cancer cells

Authors:
- Tianxiao Li
- Gang Yuan
- Lin Zhang
- Lijun Ye
- Shuxia Li
- Yuhua Fan
- Jian Sun
View Affiliations

Affiliations: Department of Clinical Research, Sun Yat‑sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China, Department of Geriatrics, The First Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Neurology, The First Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China
Published online on: September 8, 2015 https://doi.org/10.3892/mmr.2015.4299
Pages: 6976-6984

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is a worldwide malignancy of high incidence and mortality. At present, there is a lack of effective drugs against CRC. The B‑cell leukemia/lymphoma 2 (Bcl‑2) protein family members are considered to be closely associated with tumorigenesis and the chemoresistance of CRC. As a novel gossypol derivative targeting antiapoptotic proteins of the Bcl‑2 family, apogossypolone (ApoG2) exhibits antitumor properties in various cancer types, although its effects against CRC remain to be fully elucidated. In the present study, the cytotoxicity of ApoG2 in vitro on CRC cells was investigated, with the aim of elucidating the underlying mechanism. Using an MTT assay, ApoG2 was revealed to inhibit the growth of the HT29, SW480 and HCT116 CRC cell lines in a dose‑ and a time‑dependent manner. Hoechst staining revealed that ApoG2 induced CRC cell apoptosis, marked by morphological changes, including cell shrinkage and nuclear fragmentation. Flow cytometric analysis also detected a higher apoptotic ratio following treatment with ApoG2. The ratio was dependent upon the concentration of ApoG2, which the cells were exposed to, and the duration of the exposure. Western blot analysis and immunoprecipitation experiments revealed that ApoG2 treatment led to the downregulation of the protein expression of Mcl‑1, and the interruption of the binding of Mcl‑1 to the protein Bax. Furthermore, treatment with ApoG2 led to the release of cytochrome c into the cytoplasm and the activation of caspases 3 and 7. The present study revealed that ApoG2 inhibited the proliferation of the CRC cell lines through mitochondrial signaling pathway‑dependent apoptosis, which may be associated with the disruption of the function of the Mcl‑1 protein by ApoG2.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F and de Gramont A: Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009. View Article : Google Scholar
3	Reed JC: Dysregulation of apoptosis in cancer. Cancer J Sci Am. 4(Suppl 1): S8–S14. 1998.PubMed/NCBI
4	Adams JM and Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
5	Reed JC: Bcl-2 family proteins. Oncogene. 17:3225–3236. 1998. View Article : Google Scholar
6	Joensuu H, Pylkkanen L and Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol. 145:1191–1198. 1994.PubMed/NCBI
7	Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
8	Ligueros M, Jeoung D, Tang B, Hochhauser D, Reidenberg MM and Sonenberg M: Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Br J Cancer. 76:21–28. 1997. View Article : Google Scholar : PubMed/NCBI
9	Jiang J, Kulp SK, Sugimoto Y, Liu S and Lin YC: The effects of gossypol on the invasiveness of MAT-LyLu cells and MAT-LyLu cells from the metastasized lungs of MAT-LyLu-bearing Copenhagen rats. Anticancer Res. 20:4591–4597. 2000.
10	Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT, Wood BA and Leopold L: Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol. 6:781–785. 2011. View Article : Google Scholar : PubMed/NCBI
11	Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, et al: Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 23:1803–1808. 2012. View Article : Google Scholar
12	Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, Murphy SC, Erlichman C, Rudin CM, Govindan R, et al: A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 6:1757–1760. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M and Reed JC: Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood. 111:3211–3219. 2008. View Article : Google Scholar : PubMed/NCBI
14	Hu ZY, Zhu XF, Zhong ZD, Sun J, Wang J, Yang D and Zeng YX: ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopha-ryngeal carcinoma xenografts. Int J Cancer. 123:2418–2429. 2008. View Article : Google Scholar : PubMed/NCBI
15	Niu X, Li S, Wei F, Huang J, Wu G, Xu L, Xu D and Wang S: Apogossypolone induces autophagy and apoptosis in breast cancer MCF-7 cells in vitro and in vivo. Breast Cancer. 21:223–230. 2014. View Article : Google Scholar
16	Xin J, Zhan Y, Liu M, Hu H, Xia L, Nie Y, Wu K, Liang J and Tian J: ApoG2 induces ER stress-dependent apoptosis in gastric cancer cells in vitro and its real-time evaluation by bioluminescence imaging in vivo. Cancer Lett. 336:260–269. 2013. View Article : Google Scholar : PubMed/NCBI
17	Cheng P, Ni Z, Dai X, Wang B, Ding W, Rae Smith A, Xu L, Wu D, He F and Lian J: The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular carcinoma [corrected] cells. Cell Death Dis. 4:e4892013. View Article : Google Scholar
18	Zhang X, Hu X, Mu S, Zhan Y, An Q, Liu Z and Huang X: Apogossypolone inhibits the proliferation of LNCaP cells in vitro and in vivo. Mol Med Rep. 10:1184–1194. 2014.PubMed/NCBI
19	Sun J, Li ZM, Hu ZY, Zeng ZL, Yang DJ and Jiang WQ: Apogossypolone inhibits cell growth by inducing cell cycle arrest in U937 cells. Oncol Rep. 22:193–198. 2009.PubMed/NCBI
20	Prabhudesai SG, Rekhraj S, Roberts G, Darzi AW and Ziprin P: Apoptosis and chemo-resistance in colorectal cancer. J Surg Oncol. 96:77–88. 2007. View Article : Google Scholar : PubMed/NCBI
21	Mi JX, Wang GF, Wang HB, Sun XQ, Ni XY, Zhang XW, Tang JM and Yang DJ: Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma. Acta Pharmacol Sin. 29:1467–1477. 2008. View Article : Google Scholar : PubMed/NCBI
22	Sun Y, Wu J, Aboukameel A, Banerjee S, Arnold AA, Chen J, Nikolovska-Coleska Z, Lin Y, Ling X, Yang D, et al: Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biol Ther. 7:1418–1426. 2008. View Article : Google Scholar : PubMed/NCBI
23	Wang X, Wang J, Wong SC, Chow LS, Nicholls JM, Wong YC, Liu Y, Kwong DL, Sham JS and Tsa SW: Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci. 67:2663–2671. 2000. View Article : Google Scholar : PubMed/NCBI
24	Tuszynski GP and Cossu G: Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma and other tissue culture cell lines. Cancer Res. 44:768–771. 1984.PubMed/NCBI
25	Lombardi L, Frigerio S, Collini P and Pilotti S: Immunocytochemical and immunoelectron microscopical analysis of BCL2 expression in thyroid oxyphilic tumors. Ultrastruct Pathol. 21:33–39. 1997. View Article : Google Scholar : PubMed/NCBI
26	Wei J, Stebbins JL, Kitada S, Dash R, Zhai D, Placzek WJ, Wu B, Rega MF, Zhang Z, Barile E, et al: An optically pure apogossypolone derivative as potent pan-active inhibitor of antiapoptotic bcl-2 family proteins. Front Oncol. 1:282011. View Article : Google Scholar
27	Weng C, Li Y, Xu D, Shi Y and Tang H: Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem. 280:10491–10500. 2005. View Article : Google Scholar : PubMed/NCBI
28	Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ and Shibata D: Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 10:188–193. 2011. View Article : Google Scholar : PubMed/NCBI
29	Chen J, Chen Y and Chen Z: MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest. 31:17–23. 2013. View Article : Google Scholar : PubMed/NCBI
30	Poincloux L, Durando X, Seitz JF, Thivat E, Bardou VJ, Giovannini MH, Parriaux D, Barriere N, Giovannini M, Delpero JR and Monges G: Loss of Bcl-2 expression in colon cancer: A prognostic factor for recurrence in stage II colon cancer. Surg Oncol. 18:357–365. 2009. View Article : Google Scholar